Study of MDX-H210 and GM-CSF in Advanced Prostate Cancer
Author Information
Author(s): James N D, Atherton P J, Jones J, Howie A J, Tchekmedyian S, Curnow R T
Primary Institution: CRC Institute for Cancer Studies, University of Birmingham
Hypothesis
Is the bispecific antibody MDX-H210 effective in treating HER2+ advanced prostate cancer?
Conclusion
The combination of GM-CSF and MDX-H210 shows activity in hormone refractory prostate cancer with manageable toxicity.
Supporting Evidence
- 35% of evaluable patients had a greater than 50% PSA response.
- 58% of patients with evaluable pain reported improvements in pain scores.
- 83% of assessable patients showed a decrease in PSA relative velocity on therapy.
Takeaway
This study tested a new treatment for prostate cancer and found that it helped some patients feel better without causing too many bad side effects.
Methodology
Patients received MDX-H210 and GM-CSF for 4 days weekly for 6 weeks, with follow-up for toxicity and response.
Limitations
Some patients received less than the full treatment, and the follow-up duration varied.
Participant Demographics
Patients with HER2+ advanced prostate cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website